ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Imatinib (STI571, Gleevec®, Glivec®) is typically used to inhibit the tyrosine kinase activity of the BCR-ABL protein in CML therapy; however, specific CML patients are unresponsive to imatinib treatment (29).